Home » Cancer Articles » Unique medical Breakthroughs in the world of cancer
Unique medical Breakthroughs in the world of cancer
Novartis Oncology, the leader in the industry of medicine in the cancer treatment field,
/Cancer PR News/ - AMMAN, JORDAN, June 26, 2008 - recently announced new data about Zometa(Zoledronic Acid) a drug used to prevent or delay skeletal-related events in patients with advanced malignancies involving bone across a broad range of tumors.. New independent study found that Zometa (Zoledronic Acid) when added to hormone therapy, following surgery, significantly reduced the risk of cancer recurrence or death by 36% beyond clinical benefits achieved with hormone therapy alone in premenopausal women with early-stage breast cancer.
This was announced at the Annual American Society of Clinical Oncology (ASCO) meeting held in Chicago last month, the most important conference to deliver new scientific researches in the field of cancer worldwide. On this note Dr. Sami Khatib, Secretary General of Arab Medical Association Against Cancer "AMAAC" held a press conference in Amman, Jordan, to discuss the impact of this finding on cancer patients in the Arab region.
He explained that in the year 2005, Jordan recorded around 684 new breast cancer cases in women and 10 breast cancer cases in men. These cancer cases are apt to increase in the coming years.
Dr. Khatib said: "The research we are unraveling today has proven that Zometa can serve to re-shape the way we treat cancer around the world".
The independent study was led by Dr. Michael Gnant, M.D., of the Medical University of Vienna. The research enrolled 1,803 premenopausal women taking hormone therapy for early-stage breast cancer. It was found that Zometa when added to hormone therapy cut by one-third the chances of cancer reoccurrence or death beyond clinical benefits achieved with hormone therapy alone.
"This in itself is an important finding that may well change the medical practices in this field". Said Dr Sami El Khatib.
"Three-fourths of breast cancer cases occur in women after menopause. Although no research has been done to date about the effect of Zometa on this segment, it may well be that this drug is capable of being the torch of hope for older women receiving cancer too" said Dr Sami El Khatib.
"Only 30-40 % of cancer patients are cured, mainly when we discover the disease in a late stage, therefore the result of this research is a revolt that expectantly will change the concept of treatment in the world of cancer, and change the horizon for many many patients." said Dr. Khatib. |
|
FURTHER RELATED RESOURCES:
|
Press Release Contact Information:
FMK FMK
SACCS/TRACCS (Jordan Office)
MD
Shemisani
Amman, 11196
jordan 11196
Voice: 0096265660541
Fax: 0096265660542
|
|
|
|
|
|
|
Advertise With Us |
About Us |
Contact Us
